Around 700,000 Australians turn to medicinal cannabis for health issues each year, with sales skyrocketing fourfold since 2022. Yet most products bypass rigorous testing by the Therapeutic Goods Administration (TGA), sparking debates on safety and efficacy.
Major Review Examines Mental Health Benefits
The largest analysis to date, featured in Lancet Psychiatry, scrutinizes 54 randomized controlled trials spanning 1980 to 2025. These gold-standard studies target top prescription reasons: anxiety, sleep disorders, PTSD, insomnia, depression, and ADHD, alongside substance use disorders like cannabis, cocaine, and opioid dependency.
Results show scant proof that medicinal cannabis outperforms placebos for these conditions. Side effects remain mostly mild to moderate, though lingering safety concerns persist.
Breakdown of Available Evidence
Cannabidiol (CBD), a non-intoxicating option, leads evaluations, trailed by psychoactive THC and THC-CBD blends. Trials confirm no superior relief for psychotic disorders (e.g., schizophrenia), anxiety, PTSD, anorexia, or opioid use.
One bright spot: oral CBD-THC oils help curb cravings, potentially aiding those with cannabis use disorder to cut back on high-THC smoking and avert issues like lung damage.
Safety Insights and Real-World Gaps
Participants report minor issues like nausea, dry mouth, and fatigue. Serious risks, such as psychotic episodes, match placebo rates. However, trials last just five weeks on average, ignoring long-term effects from chronic use.
High-THC products dominate Australian access, heightening mental health risks—especially for youth. Recent data indicates one-quarter of medicinal users develop dependency, mirroring recreational patterns.
Study Limitations Highlight Caution
Encouraging hints for Tourette’s syndrome, insomnia, and autism rely on sparse, low-quality trials. Intoxicating effects compromise blinding, while conflicts of interest cloud some outcomes.
Findings echo prior analyses, underscoring a disconnect: short-term, low-THC research versus prolonged, high-THC real-world application.
Path Forward for Research and Policy
Expanded, long-term studies are crucial, particularly for underserved conditions. As TGA reviews prescribing practices, evidence should shape rules to curb harms and promote proven therapies.
Practical Advice for Users
Personal benefits do not contradict the data. Consult physicians routinely and weigh evidence-backed alternatives for optimal care.
